Rapid measurement of plasma methadone in a clinical setting using florescence polarization immunoassay

Journal of Addictive Diseases

Volumn 15, Issue 2, 1996, Pages 69-83

  Kell, Michael Jon ^a,c   Techman, Thomas ^b  

^a Private Clinic Laboratories   (United States)

^b Doctors and Physicians Laboratory   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; OPIATE;

ARTICLE; CALIBRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METHADONE TREATMENT; OUTPATIENT; TIME;

EID: 0029924318     PISSN: 10550887     EISSN: None     Source Type: Journal    
DOI: 10.1300/J069v15n02_06     Document Type: Article

References (20)

1. Kell M, Musselman D, Methadone prophylaxis of intractable headaches: Pain control and serum opioid levels. J Pain Management 1993;3:7-14.
2. Kell M. Long-term methadone maintenance for intractable, non-malignant pain: Pain control and plasma opioid levels. J Pain Management 1994;4:10-16.
3. Kell M. Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: Measurement techniques for a clinical setting. J Addictive Dis 1993; 13:5-26.
4. Beck O, Boreus LO, Borg S, Jacobson G, Lafolie P, Stensio M. Monitoring of plasma methadone: intercorretation between immunoassay and gas chromatography-mass spectrometry. Ther Drug Monitoring 1990;12:473-477.
5. Wolff K, Sanderson M, Hay A, Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem 1991;37:205-209.
6. Wolff K, Hay A, Raistrick D. High-dose methadone and the need for drug measurements in plasma. Clin Chem 1991;37:1651-1664.
7. Wolff K, Hay A. Methadone in saliva. Clin Chem 1991;37:1297-1298.
8. Nilsson MI, Widerlov E, Meresaar U, Anggard E. Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol 1982;22:337-342.
9. Nilsson MI, Anggard E, Holmstrand J, Gunne LM. Pharmacokinetics of methadone in methadone maintenance treatment: Adaptive changes during the induction phase. Eur J Clin Pharmacol 1982;22:343-349.
10. Liu SJ, Roerig DL, Wang RIH. Brain and plasma levels of methadone and their relationships to analgesic activity of methadone in rats. Drug Metabol Disposition 1983;11:335-338.
11. Dole V. Implications of methadone maintenance for theories of narcotic addiction. JAMA 1988;260:3025-3029.
12. Sullivan HR, Smits SE, Due SL, Booher RE, McMahon RE. Metabolism of methadone: Isolation and identification of analgesically active metabolites. Life Sci 1972;11:1093-1104.
13. Sullivan HR, Due SL. Urinary metabolites of dl-methadone in maintenance subjects. J Medicinal Chem 1973;16:909-913.
14. Kreek MJ, Benesath FA, Field FH. Effects of liver disease on urinary excretion of methadone and metabolites in maintenance patients: Quantitation by direct probe chemical ionization mass spectrometry. Biomed Mass Spectrometry 1980;7:385-395.
15. Adams AK, Essien H, Binder SR. Identification of drugs in physiological fluids following on-line Chromatographic purification and analysis. Ann Bio Clin 1991;49:291-297.
16. Binder SR, Regalia M, Biaggi-McEachern M, Mazhar MJ. Automated liquid Chromatographic analysis of drugs in urine by on-line sample cleanup and isocratic multi-column separation. J Chromatography 1989;473(2):325-341.
17. Binder SR, Regalia M, Sivorinovsky G. Toxicological screening by liquid Chromatography. Trends Anal Chem 1989;8(10):362-367.
18. Binder SR, Adams AK, Regalia M, Essien H, Rosenblum RJ. Standardization of a multi-wavelength UV detector for liquid chromatography-based toxicological analysis. Chromatography 1991;550(1-2):449-459.
19. Broderik N, Gerson B, Binder SR, Essien H. Identification and quantification of methadone and its primary metabolite using REMEDi Drug Profiling System. Presented at the 2nd International Congress of Therapeutic Drug Monitoring and Toxicology, Barcelona, Spain, October 11, 1990.
20. Kell MJ. Utilization of plasma and urine methadone concentrations to limit narcotics use in methadone maintenance patients: II. Generation of plasma concentration curves. J Addictive Dis 1995; 14(1):85-100.